MeiraGTx appoints Alan M. Sebulsky to Board as Class I director effective Sept 23, 2026

MeiraGTx Holdings plc

Sebulsky, Managing Member of Apothecary Capital, joins as Class I director with term expiring at 2028 annual meeting.
Appointed to Science and Technology Committee; eligible for Non-Employee Director Compensation.
Ex-Partner at Adage Capital for 14 years, managing a biopharma portfolio with over $2B in assets.
Current board member of Parabilis Medicines; former director of Jazz Pharmaceuticals and Arrow International.
CEO Alexandria Forbes cites his 25-year relationship and biopharma investing experience as valuable as company transitions to commercial.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alan M. Sebulsky

Class I Director

MGTX · MeiraGTx Holdings plc

Effective: 2026-09-23
Filed: September 23, 2026, 8:12 AM ET

appointed Alan M. Sebulsky to the Board as a Class I director, effective September 23, 2026

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alan M. Sebulsky was appointed as Class I Director at MeiraGTx Holdings plc.

Action: appointed
Role: Class I Director

Exact text from the filing

appointed Alan M. Sebulsky to the Board as a Class I director, effective September 23, 2026

View on SEC.gov

MeiraGTx Holdings plc filing history →

Source: SEC EDGAR

accession 0001104659-26-109824

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.